Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William H Sharfman

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Pain|June 1, 1990
Has the analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain?William H Sharfman, Declan T Walsh
Biologics : Targets & Therapy|November 26, 2015
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitorsLeslie A Fecher, William H Sharfman
Ejhaem|December 5, 2022
Bing-Neel syndromeKatelynn Davis, William H Sharfman, Ivo M B Francischetti
Cancer Biology & Therapy|September 30, 2015
Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanomaTasha Hughes, Matthew Klairmont, William H Sharfman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanomaEvan J Lipson, Mabel A Bodell, Edward S Kraus, et al.
World Journal of Gastroenterology|April 5, 2017
Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitisAnimesh Jain, Evan J Lipson, William H Sharfman, et al.
Case Reports in Medicine|July 25, 2014
Primary small cell neuroendocrine carcinoma of paranasal sinusesMaliha Khan, Sobia Nizami, Aibek E Mirrakhimov, et al.
Journal for Immunotherapy of Cancer|July 10, 2019
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case seriesJaclyn LoPiccolo, Megan D Schollenberger, Sumia Dakhil, et al.
Journal for Immunotherapy of Cancer|March 28, 2017
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockadeEvan J Lipson, Mohammed T Lilo, Aleksandra Ogurtsova, et al.
International Journal of Cancer|June 26, 2016
BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasisRussell Maxwell, Tomas Garzon-Muvdi, Evan J Lipson, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Pain|June 1, 1990
Has the analgesic efficacy of neurolytic celiac plexus block been demonstrated in pancreatic cancer pain?William H Sharfman, Declan T Walsh
Biologics : Targets & Therapy|November 26, 2015
Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitorsLeslie A Fecher, William H Sharfman
Ejhaem|December 5, 2022
Bing-Neel syndromeKatelynn Davis, William H Sharfman, Ivo M B Francischetti
Cancer Biology & Therapy|September 30, 2015
Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanomaTasha Hughes, Matthew Klairmont, William H Sharfman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 5, 2014
Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanomaEvan J Lipson, Mabel A Bodell, Edward S Kraus, et al.
World Journal of Gastroenterology|April 5, 2017
Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitisAnimesh Jain, Evan J Lipson, William H Sharfman, et al.
Case Reports in Medicine|July 25, 2014
Primary small cell neuroendocrine carcinoma of paranasal sinusesMaliha Khan, Sobia Nizami, Aibek E Mirrakhimov, et al.
Journal for Immunotherapy of Cancer|July 10, 2019
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case seriesJaclyn LoPiccolo, Megan D Schollenberger, Sumia Dakhil, et al.
Journal for Immunotherapy of Cancer|March 28, 2017
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockadeEvan J Lipson, Mohammed T Lilo, Aleksandra Ogurtsova, et al.
International Journal of Cancer|June 26, 2016
BRAF-V600 mutational status affects recurrence patterns of melanoma brain metastasisRussell Maxwell, Tomas Garzon-Muvdi, Evan J Lipson, et al.
Pageof 4